Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-440 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort C1 | EXPERIMENTAL | - |
| Cohort C1: Triple Placebo | PLACEBO_COMPARATOR | - |
| Cohort C2 | EXPERIMENTAL | - |
| Cohort C2: Triple Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VX-440 | DRUG | VX-440 was administered in TC with TEZ and IVA. |
| TEZ | DRUG | TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA) |
| IVA | DRUG | IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet |
| Matched Placebos | DRUG | Placebos matched to VX-440, TEZ, and IVA. |
Inclusion Criteria: * Female subjects of non-childbearing potential only. * Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight \>50 kg. * Normal pulmonary function measurements, defined as forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) both ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
VX-440 is an investigational small molecule being developed for the treatment of cystic fibrosis. It is being studied in combination with tezacaftor and ivacaftor, which are other cystic fibrosis therapies. The drug is currently in Phase 1 clinical development.
VX-440 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company. Vertex is publicly traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of VX-440.
VX-440 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a Phase 1 clinical trial to evaluate its safety and pharmacokinetics in healthy adult subjects.
VX-440 has one completed clinical trial, identified as NCT03486236. This was a Phase 1 study evaluating the safety and pharmacokinetics of VX-440 in combination with tezacaftor and ivacaftor in healthy adult subjects. The trial was conducted in the United Kingdom and enrolled 16 participants.
No, VX-440 is a distinct investigational drug from tezacaftor and ivacaftor. In clinical trials, VX-440 is being studied in combination with tezacaftor and ivacaftor, which are separate medications used to treat cystic fibrosis. VX-440 is not an alternative name for either of these drugs.